Extracellular Galectin-3 in Tumor Progression and Metastasis by Anneliese Fortuna-Costa et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 16 June 2014
doi: 10.3389/fonc.2014.00138
Extracellular galectin-3 in tumor progression and
metastasis
Anneliese Fortuna-Costa, Angélica M. Gomes, Eliene O. Kozlowski , Mariana P. Stelling and
Mauro S. G. Pavão*
Programa de Glicobiologia, Laboratório de Bioquímica e Biologia Celular de Glicoconjugados, Instituto de Bioquímica Médica Leopoldo de Meis, Hospital
Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Edited by:
Adriane Regina Todeschini,
Universidade Federal do Rio de
Janeiro, Brazil
Reviewed by:
Olivier Micheau, Institut National de la
Santé et de la Recherche Médicale,
France
TeizoYoshimura, National Cancer
Institute, USA
*Correspondence:
Mauro S. G. Pavão, Programa de
Glicobiologia, Laboratório de
Bioquímica e Biologia Celular de
Glicoconjugados, Instituto de
Bioquímica Médica Leopoldo de
Meis, Hospital Universitário
Clementino Fraga Filho, Universidade
Federal do Rio de Janeiro, Rua
Rodolpho Paulo Rocco 255, 4° andar,
Sala 4A-08, Cidade Universitária, Rio
de Janeiro, Rio de Janeiro 21941 913,
Brazil
e-mail: mpavao@hucff.ufrj.br
Galectin-3, the only chimera galectin found in vertebrates, is one of the best-studied
galectins. It is expressed in several cell types and is involved in a broad range of physiolog-
ical and pathological processes, such as cell adhesion, cell activation and chemoattraction,
cell cycle, apoptosis, and cell growth and differentiation. However, this molecule raises
special interest due to its role in regulating cancer cell activities. Galectin-3 has high affin-
ity for β-1,6-N -acetylglucosamine branched glycans, which are formed by the action of the
β1,6-N -acetylglucosaminyltransferaseV (Mgat5). Mgat5-related changes in protein/lipid gly-
cosylation on cell surface lead to alterations in the clustering of membrane proteins through
lattice formation, resulting in functional advantages for tumor cells. Galectin-3 presence
enhances migration and/or invasion of many tumors. Galectin-3-dependent clustering of
integrins promotes ligand-induced integrin activation, leading to cell motility. Galectin-3
binding to mucin-1 increases transendothelial invasion, decreasing metastasis-free sur-
vival in an experimental metastasis model. Galectin-3 also affects endothelial cell behavior
by regulating capillary tube formation. This lectin is found in the tumor stroma, suggesting
a role for microenvironmental galectin-3 in tumor progression. Galectin-3 also seems to
be involved in the recruitment of tumor-associated macrophages, possibly contributing to
angiogenesis and tumor growth.This lectin can be a relevant factor in turning bone marrow
in a sanctuary for leukemia cells, favoring resistance to therapy. Finally, galectin-3 seems
to play a relevant role in orchestrating distinct cell events in tumor microenvironment and
for this reason, it can be considered a target in tumor therapies. In conclusion, this review
aims to describe the processes of tumor progression and metastasis involving extracellular
galectin-3 and its expression and regulation.
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INTRODUCTION
Galectins comprise a family of animal lectins defined by their abil-
ity to recognize β-galactoside-containing glycoconjugates through
a conserved carbohydrate-recognition domain (CRD). Based on
molecular architecture, the 15 members of the galectin family
are divided into 3 main groups: (1) prototype galectins, (2) tan-
dem repeat galectins, and (3) chimera galectins. While prototype
galectins are usually homodimers with two polypeptides contain-
ing a CRD each, tandem repeat galectins are monomers presenting
two CRDs, connected by a linker region. Chimera galectins, in
turn, consist of one CRD connected to a collagen-like sequence
formed by Pro-Gly-Tyr tandem repeats and an N-terminal domain
(Figure 1A). Some galectins are present in a variety of tissues, while
others have a more specific localization. Galectins are involved in
physiological and pathological events, such as cell proliferation
and differentiation, apoptosis, immune response, cell differentia-
tion, and tumor progression. The mechanisms underlying these
aspects are currently under massive investigation.
Galectin-3, the only chimera galectin found in vertebrates, is
one of the best-studied galectins. It is a versatile 29–35 kDa pro-
tein that participates in several biological processes: cell adhesion,
cell activation and chemoattraction, cell growth and differenti-
ation, cell cycle, and apoptosis (1–4). Galectin-3 occurs mainly
in the cytosol, but can also transverse membranes reaching the
nucleus (5) and mitochondria (6, 7). In general, galectins lack
a signal peptide that would direct them to the classical secre-
tory pathway; nevertheless, galectin-3 has been encountered in
the extracellular environment. Once in the extracellular space,
galectin-3 can interact with innumerous binding partners, mostly
polylactosamine-rich molecules in the extracellular matrix (ECM)
or on the cell surface, and plays key roles in the extracellular
modulation of tumor progression (1, 8). The non-classical mech-
anism for galectin-3 secretion is not clear, but data obtained so
far suggest that galectin-3 is secreted via exosomes (9) and its N-
terminal domain is responsible for locating galectin-3 into these
structures (10).
Despite galectin-3 expression in a variety of cell types and its
involvement in several biological processes, this molecule raises
special interest due to its remarkable role in regulating a broad
range of cancer cell activities (11). Indeed, galectin-3 is often over-
expressed in various human solid tumors and blood malignancies
and, in many cases, this altered expression correlates with the stage
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FIGURE 1 | Galectin-3 structure. Schematic representation of (A) galectin-3 monomer and (B) galectin-3 oligomerization through its N-terminal domain in the
presence of its binding partners.
of tumor progression, suggesting an influence of this molecule in
disease outcome (2).
There are multiple lines of evidence pointing to the relevance
of galectin-3 in malignant cell transformation (12, 13), tumor
growth (14, 15), anoikis resistance (16), apoptosis inhibition (17,
18), angiogenesis (19, 20), cell adhesion (21, 22), cell motility (23),
and cell invasion (24, 25). The last four are important steps of the
metastatic process, in which extracellular, rather than intracellular
galectin-3, plays a prominent role in both tumor cells and stromal
cells present in the tumor microenvironment (19, 26–28).
In this review, we aim to examine recent data regarding the
extracellular functions of galectin-3 in some steps of tumor pro-
gression and metastasis. We also discuss how cells at the tumor
microenvironment may contribute to extracellular galectin-3
mediated tumor progression.
GALECTIN-3 BINDING PARTNERS
GALECTIN-3 HAS HIGH AFFINITY FOR β-1,6-N -ACETYLGLUCOSAMINE
BRANCHED GLYCANS
Glycosylation is the most common post-translational modifica-
tion occurring in proteins, with nearly half of all known proteins
in eukaryotes being glycosylated. The presence of oligosaccharide
moieties in proteins secreted or expressed on the cell surface affects
protein conformation and localization. The structural complex-
ity of oligosaccharides brings bio-specific information, mediat-
ing highly relevant molecular and cellular interactions. Indeed,
changes in oligosaccharide structures are associated with many
physiological and pathological events, such as cell growth (29),
migration (30, 31), cell adhesion (32), endocytosis (33), trans-
membrane signaling (34, 35) autoimmunity, metabolic syndrome
(36), and tumor development and metastasis (37, 38).
The tumor microenvironment is characterized by aberrant gly-
cosylation, with oligosaccharide under- or overexpression and
presence of novel carbohydrate moieties. These aberrations are
mostly due to changes in the expression levels of glycosyltrans-
ferases in the Golgi compartment of cancer cells. Several evidences
point to an increase in size and branching of N-linked glycans as
a remarkable feature of colon and breast cancer (39, 40). This
change is usually attributed to the increased activity or expres-
sion of β1,6-N -acetylglucosaminyltransferase V (Mgat5). This
Golgi enzyme catalyzes the addition of β1,6-N -acetylglucosamine
to both tetra-antennary N-linked and O-linked oligosaccharides,
forming multi-antennary chains. These longer and more branched
chains bind to galectins with higher affinity than less branched
glycans (41, 42). Mgat5 is indeed responsible for the synthesis of
preferred binding partners for galectins (2).
Galectin-3 has high affinity for β-1,6-N -acetylglucosamine
branched glycans. Such interaction mediates binding of the lectin
to many glycoproteins and glycolipids in the cell membrane,
including carcinoembryonic antigen (CEA), mucin-1, lysosomal-
membrane-associated glycoproteins (LAMPs)-1 and -2, Mac-1
and Mac-3, CD-98, CD-45, CD-71 (43–46), and the glycosylated
transmembrane tyrosine kinase receptors for epidermal growth
factor (EGF) (42, 47), transforming growth factor beta (TGF-β)
(42), vascular endothelial growth factor (VEGF) (48), and others.
Mgat5-related changes in protein/lipid glycosylation and density
on cell surface lead to alterations in the clustering of those mem-
brane proteins through lattice formation, resulting in functional
advantages for tumor cells (see below). A list of the main galectin-3
binding partners is shown in Table 1.
Increased β1-6 branching of other Mgat5 target proteins, such
as cadherins, integrins, and other cytokine/growth factor recep-
tors may enhance and promote tumor growth and metastasis
(22, 23, 55). On the other hand, Mgat5 knockout (KO) mice
have been shown to present suppressed polyomavirus middle T
antigen-induced tumor growth and metastasis (56). Despite the
low number of papers published on the direct effects of Mgat5
activity on galectin-3 function, both proteins are increased dur-
ing tumor progression and deserve attention as suitable targets in
malignant diseases.
LATTICE FORMATION
Lattices are multivalent complexes of soluble galectins and glyco-
protein receptors on the cell surface. These structures are impor-
tant for organization of glycoprotein assemblies on the cell sur-
face. Recent works have shown, through genetic and biochemical
manipulation of glycosylation pathways or galectins themselves,
that galectin–glycoprotein lattices affect the control of biological
processes, including glycoprotein receptor turnover and endo-
cytosis among other biological processes. Thereby, formation of
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Table 1 | Galectin-3 binding partners.
Molecule Reference
1. Carcinoembryonic antigen (43–46)
2. Mucin-1
3. Lysosomal-membrane-associated glycoproteins-1 and -2
4. Mac-1 and -3
5. CD-98
6. CD-45
7. CD-71
8. Fibronectin (49)
9. Collagen IV (50)
10. Elastin (51)
11. Laminin (49)
12. Hensin (49)
13. N-cadherin (22)
14. Desmoglein (52)
15. αvβ3 Integrin (53)
16. VEGFR-2 (48)
17. NG2 (neuron-glial antigen 2) chondroitin sulfate
proteoglycan
(54)
18. α3β1-Integrin (54)
galectin–glycan lattices may extend exposition of glycoproteins on
the cell surface, affecting cell response to receptors ligands (57, 58).
Intracellular galectin-3 is mostly a monomeric soluble protein
(59). Upon interaction of a monomeric galectin-3 with glycopro-
teins or glycolipids, additional galectin-3 monomers are linked
to the complex through their N-terminal domain, establishing
pentameric structures (Figure 1B) (1). This complex of mul-
tivalent interactions cross-links carbohydrate-containing glyco-
proteins or glycolipids, promoting the formation of organized
galectin–glycan clusters termed lattices and modulating cell func-
tions (Figure 2) (60, 61). Ultimately, galectin-3 helps to organize
functional microdomains on the cell surface assuring proper trans-
mission of extracellular signals into the cell (57, 58). It is worth
emphasizing that the glycosylation pattern of galectin-3 binding
partners is determinant for extracellular galectin-3 binding and
lattice formation on the cell surface (33, 57).
EXTRACELLULAR GALECTIN-3 IN THE
INVASION-METASTASIS CASCADE
During tumor progression, some cancer cells become capable of
invading surrounding tissues, disseminating through blood or
lymphatic vessels, penetrating basement membranes and endothe-
lial walls, extravasating into parenchyma and colonizing distant
organs (62). Although it is thought that only a few cells in the
primary tumor are able to succeed in all these steps, this complex
and dynamic process accounts for the majority of cancer-related
deaths (63).
At the mechanistic level, invasion and metastasis processes
involve changes in several classes of proteins engaged in cell–cell
and cell–matrix adhesion, as well as in signaling pathways that
control cytoskeletal dynamics (64). Extracellular galectin-3 seems
to contribute to these processes and might have relevance in the
invasion-metastasis cascade.
REGULATION OF TUMOR INVASIVENESS BY EXTRACELLULAR
GALECTIN-3
The migratory and invasive activation of tumor cells is often asso-
ciated with tumor progression (64). Galectin-3 expression was
shown to increase migration and/or invasion of many tumor types,
such as breast cancer (65), melanoma (14), lung cancer (66), sar-
coma (67), gastric cancer (68), and chronic myelogenous leukemia
(CML) in vitro (27). However, specific dependence on extracellular
galectin-3 has not been determined in most of these studies.
The adhesive interaction with ECM binding partners is impor-
tant for cell migration (64). In this regard, galectin-3 was shown
to interact with ECM glycoproteins such as fibronectin, collagen
IV, elastin, laminin, and hensin (49–51, 69). Moreover, exoge-
nously added galectin-3 interacts with Mgat5-modified N-linked
oligosaccharides on the surface of mammary carcinoma cells and
stimulates α5β1-integrin activation, enhancing fibronectin fibril-
logenesis and fibronectin-dependent tumor cell spreading, and
motility (70). Therefore, galectin-3-dependent integrin cluster-
ing promotes integrin activation as well as ligand-induced inte-
grin activation (70). Additionally, Src kinase-dependent caveolin-
1 (Cav1) phosphorylation increases focal adhesion turnover,
RhoA activation, and tumor cell migration in a galectin-3-
dependent manner. Interestingly, galectin-3 and phosphorylated
Cav1 (pCav1) act synergistically in this context, because overex-
pression of a non-phosphorylatable Cav1 mutant or disruption
of galectin-3 lattice inhibit cell motility (71, 72). More recently,
Boscher and Nabi showed that galectin-3 and pCav1-dependent
integrin signaling mediate EGF stimulation of actin reorganization
in circular dorsal ruffles, cell migration, and fibronectin remod-
eling. The authors proposed that Mgat5-dependent galectin-3
lattice enables EGF signal transduction that triggers galectin-3-
dependent integrin activation. Then, the active integrin induces
Src-dependent phosphorylation of Cav1 and RhoA/ROCK signal-
ing (23).
De novo expression of galectin-3 in a galectin-null sarcoma cell
line decreased cell adhesion to laminin-111 and promoted their
migratory capacity on the same substratum, in a carbohydrate-
dependent manner. Migratory modulation was associated with
disassembly of stable focal adhesion plaque, as evaluated by the
decrease of phosphorylated focal adhesion kinase (FAK) in lamel-
lipodia of migrating cells and phospho-paxillin in focal com-
plexes. The promigratory activity was also shown to be dependent
on activation of PI-3 kinase pathway and AKT phosphoryla-
tion (67).
It is well established that loss of intercellular adhesions cor-
relates with tumor invasion and metastasis, as it allows tumor
cells to escape the primary tumor site. Indeed, during the migra-
tion process, intercellular junctions are actively remodeled (64).
Recently, it was shown that extracellular galectin-3 can bind to
N-cadherin in murine mammary cancer cells, and this association
is mediated by Mgat5-generated N -glycans. More interestingly,
galectin-3 binding to N-cadherin contributes to destabilization of
cell–cell junctions by enhancing turnover of N-cadherin and other
glycoconjugates, which might favor cell migration process (22). On
the other hand, the binding of extracellular galectin-3 to N -glycans
on desmoglein, a cadherin present on desmosomes, seems to pro-
mote the stability of cadherin at the cell surface and in epithelial
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FIGURE 2 | Galectin-3 modulates tumor cell behavior. (A) Galectin-3
monomers are secreted by a non-classical mechanism. Once in the
extracellular space, galectin-3 monomers can interact with innumerous
glycosylated molecules, such as receptors, cell–cell adhesion molecules,
integrins, and ECM molecules. Upon monomeric galectin-3 interaction with a
binding partner, additional galectin-3 monomers are linked to the complex
through their N-terminal domain, establishing pentameric structures. (B)This
complex cross-links carbohydrate-containing glycans, promoting the
formation of organized galectin–glycan clusters termed lattices and
modulating tumor cell behavior, such as (C) adhesion and (D) migration.
(E) Galectin-3-glycan lattices also extend the exposition of receptors on the
cell surface, affecting cell response to cytokines and growth factors.
intercellular adhesion on colon cancer cells (52). This extracellular
galectin-3-mediated modulation of tumor cell motility deserves
further investigation in different models.
EXTRACELLULAR GALECTIN-3 IN CELL ADHESION DURING TUMOR
DISSEMINATION
The survival of tumor cells in blood or lymphatic circula-
tion and their subsequent adhesion to vascular endothelium
represent crucial steps for colonizing secondary sites (62). In
this regard, exogenous or tumor-derived galectin-3 was shown
to increase melanoma and colon cancer cells homotypic and
heterotypic adhesions by interaction with oncofetal Thomsen–
Friedenreich carbohydrate on the cancer-associated transmem-
brane mucin protein (MUC1) (21, 45, 73). Galectin-3-MUC1
interaction increases tumor cell aggregation and favors the for-
mation of tumor micro-emboli, preventing anoikis initiation and
enhancing circulating tumor cell survival (73). The mechanism
responsible for this interaction seems to be MUC1 induction
of cell surface polarization, exposing smaller adhesion molecules
on the cell surface, including E-cadherin, CD44, and E-selectin
ligands (73, 74).
Galectin-3–MUC1 interaction was shown to enhance het-
erotypic adhesion between tumor and endothelial cells under
static and flow conditions (21, 45, 74, 75). Such interaction also
increased transendothelial invasion and decreased metastasis-free
survival in an animal model of experimental metastasis (74). In a
xenograft model, galectin-3 was shown to be upregulated in breast
tumor cells proximal to the stroma. This localized expression may
facilitate tumor–stromal interactions and consequently improve
endothelial cells adhesion, resulting in invasion and metastatic
progression (76). High expression of galectin-3 was also observed
in breast cancer patients, both on tumor cells and tumor–stromal
cells of most specimens. Interestingly, the presence of galectin-3
in tumor-associated stroma was related to unfavorable prognosis.
Nevertheless, the survival analysis disclosed no prognostic corre-
lation to either cytoplasmic or nuclear localization of galectin-3
on breast tumor cells (77).
Another metastasis-promoting role of galectin-3 results from
the crosstalk between circulating galectin-3 and endothelial cells.
Through the use of cytokine array and human microvascular lung
endothelial cells, it has been shown that high levels of galectin-3
(mimicking pathological concentrations) induce secretion of sev-
eral cytokines, such as IL-6, G-CSF, and GM-CSF in vitro and
in vivo. These cytokines enhance tumor cell adhesion to endothe-
lial cells through upregulation of E-selectin, ICAM-1, VCAM-1,
and integrin αvβ1 on endothelial cells (78).
Radosavljevic et al. also addressed galectin-3 role in tumor
metastasis. In this study, they showed that, compared with wild-
type (WT) mice, galectin-3 KO mice presented a markedly reduced
number and size of metastatic colonies in an experimental model
of lung B16F1 murine melanoma metastasis. Taking into account
in vitro data showing a lower binding of malignant cells onto lung
tissue of galectin-3 KO mice, the authors suggested the involve-
ment of stromal cell-derived galectin-3 on tumor cell adhesion to
the metastatic target. Interestingly, NK cells maturation and anti-
tumor cytotoxic activity were increased in galectin-3 KO mice.
Therefore, galectin-3 host deficiency could impair the success-
ful establishment of melanoma metastatic foci by decreasing the
binding of melanoma cells onto target tissue and by enhancing
NK-mediated anti-tumor response (28).
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TUMOR MICROENVIRONMENT RELEVANCE FOR
EXTRACELLULAR GALECTIN-3 FUNCTIONS
In the past decade many convincing observations proved that com-
munication between cancer cells and the associated stroma plays
a key role in driving tumor progression. These evidences placed a
spotlight on the relevance of understanding the tumor microen-
vironment rather than focusing studies only on the biology of
tumor cells (62, 79, 80). Tumor–stromal cells (e.g., endothelial
cells, immune and inflammatory cells, cancer-associated fibrob-
lasts, myofibroblasts, and mesenchymal stromal cells) behavior is
affected by extracellular galectin-3 and these cells are also capable
of secreting this molecule (19, 81–83). Despite these evidences,
our understanding on the role of extracellular galectin-3 present
at the tumor milieu is still limited.
EXTRACELLULAR GALECTIN-3 IN TUMOR ANGIOGENESIS
The establishment of new capillary vessels is a vital process for
continuous tumor growth and provides a pathway for dissem-
ination of malignant cells (62, 84). Previous works had shown
that human breast carcinoma cells expressing galectin-3, unlike
its galectin-3 null parental cells, progressively grew and metas-
tasized when inoculated into the mammary fat pad of athymic
nude mice (85). Nangia-Makker and co-workers hypothesized
the involvement of galectin-3 secreted by tumor cells in angio-
genesis. In fact, the authors demonstrated that extracellular
galectin-3, by means of its carbohydrate-recognition capacity,
affects endothelial cell behavior regulating capillary tube for-
mation in vitro and angiogenesis in vivo (19). Galectin-3 was
required for the stabilization of epithelial–endothelial interac-
tion networks and co-culture of these two cells types resulted
in increased levels of secreted galectin-3. However, it was not
investigated in this work whether the co-culture condition mod-
ulated galectin-3 secretion in epithelial, endothelial, or both cell
types (76).
The molecular mechanisms for galectin-3 promotion of angio-
genesis involve the binding of galectin-3 to αvβ3 integrins on
endothelial cells, inducing integrin clustering and activating sig-
naling pathways that influence VEGF and basic fibroblast growth
factor (bFGF) angiogenic activity, in addition to promoting FAK
phosphorylation (53). Furthermore, the binding of galectin-3 to
VEGFR-2 is enough to retain the receptor on the plasma mem-
brane of endothelial cells and to generate VEGFR-2-clusters that
boosts cell signaling effects (48). Additionally, neuron-glial anti-
gen 2 (NG2), a transmembrane chondroitin sulfate proteogly-
can expressed by pericytes in newly formed blood vessels, was
also shown to induce endothelial cell motility and angiogene-
sis by forming the NG2–galectin-3–α3β1 integrin complex at the
pericyte–endothelial cell interface (54).
Galectin-3 collagen-like domain is susceptible to matrix met-
alloproteinases cleavage (86). Galectin-3 cleaved form was found
in the conditioned medium of epithelial–endothelial co-cultures
(76). Compared to tumor cells harboring cleavable galectin-3,
tumor cells transfected with cleavage resistant galectin-3 showed
reduced tumor growth in athymic nude mice and diminished
angiogenesis (87). A subsequent study indicated that cleaved
galectin-3 is more efficient than intact galectin-3 in exerting
chemotactic forces upon endothelial cells through upregulation of
phosphorylated FAK, possibly leading to enhanced tumoral angio-
genesis, due to recruitment of these cells to the tumor site (20).
Interestingly, compared with intact galectin-3, cleaved galectin-
3 presented increased binding to laminin (86) and endothelial
cells (76). Therefore, the cleavage seems to improve galectin-3
affinity to binding partners. However, cleavage of the collagen-like
domain is also thought to reduce galectin-3 ability to form dimers
or higher order oligomers by self-association (86), suggesting that
extracellular galectin-3 angiogenic effects may not be essentially
dependent on lattice formation.
Considering that tumor-associated macrophages (TAM) are
known to enhance local production of VEGF (88) and galectin-3
was shown to be necessary for optimal pro-tumor macrophage
polarization (89), Machado et al. have used an interesting
approach to study the role of galectin-3 in TAM-mediated
tumor angiogenesis. Galectin-3 expression was reconstituted in
a melanoma cell line that lacks this lectin and both express-
ing galectin-3 or galectin-3 null parental cells were inoculated in
galectin-3 KO or WT mice. Interestingly, the absence of galectin-3
per se, either in melanoma cells or in the tumor stroma of galectin-
3 KO mice, reduced tumor-associated angiogenesis. Furthermore,
tumor microenvironment galectin-3 was shown to interfere with
TAM recruitment, because infiltrating CD68+ cells were observed
into the tumor mass, while these cells were only found in the
periphery of galectin-3 negative tumors engrafted in KO mice.
In vitro, galectin-3 KO mice bone marrow-derived macrophages
(BMDM) showed a reduced basal VEGF secretion when com-
pared with BMDM from WT mice, and were not responsive to
VEGF secretion induction upon TGF-β1 stimulation. Besides,
in vitro results also demonstrated that, even without any spe-
cific stimulus, galectin-3-expressing melanoma cells secrete larger
amounts of VEGF than its galectin-3 null parental cells. There-
fore, these in vitro data might explain the diminished angiogenesis
observed in vivo when galectin-3 is absent in tumor cells and/or
in the tumor stroma (26). This work reinforces the idea that
extracellular galectin-3 plays a role in the organization of tumor
microenvironment.
GALECTIN-3 IN BONE MARROWMICROENVIRONMENT
Galectin-3 KO mice were first reported as viable and without any
obvious physiological defects, suggesting that other members of
the galectin family could exert galectin-3 functions (90). In con-
trast, subsequent works showed that these mice have deficiencies
in immune/inflammatory cell accumulation and differentiation
during experimental peritonitis (91–93) and in the course of Schis-
tosoma mansoni infection (94, 95). Histological analysis of bone
marrow from galectin-3 KO mice exhibited considerable modifi-
cations with reduced cell density and increased trabecular projec-
tions into the marrow cavity. Additionally, absence of galectin-3
reduced the levels of GM-CSF gene expression in bone marrow
stromal cells (BMSC), increased the number of hematopoietic
multipotent progenitors with the concomitant decreased capac-
ity to differentiate into mature myeloid cell populations. In view
of the fact that hematological malignancies are frequently associ-
ated with BMSC disorders that disturb the hematopoietic system,
the authors propose the feasible involvement of galectin-3 in this
context (95).
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In consonance with the aforementioned supposition,
Yamamoto-Sugitani and co-workers investigated whether galectin-
3 would be involved in the intricate relationship that turns the
bone marrow microenvironment into a sanctuary for leukemia
cells by favoring resistance to therapy. In fact, in vitro results
showed that galectin-3 expression in CML cells was increased
by co-culture with BMSC. Moreover, galectin-3 overexpression
in CML cells promoted proliferation, migration toward BMSC-
derived soluble factors, and multidrug resistance. In vivo findings
showed that galectin-3 overexpression on CML cells facilitates
bone marrow homing and lodgment (27). Afterward, the group
revealed that galectin-3 overexpression on CML cells promotes
its paracrine growth by decreasing the action of the SERPINA1–
albumin complex growth inhibitor, a serine protease inhibitor
involved in various proteolytic processes on the cell surface and
on the ECM (15).
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
As addressed in this review, countless evidences point to a relevant
role of extracellular galectin-3 in crucial steps of tumor progres-
sion and metastasis. This lectin seems to orchestrate distinct events
involving several cell types that constitute the tumor microenvi-
ronment. For this reason, galectin-3 has been explored as a target
for cancer therapy. In this regard, a promising result was obtained
with specific peptides against galectin-3 CRD that were capable
of significantly inhibiting rolling and stable heterotypic adhesion
of tumor cells to endothelial cells, as well as homotypic tumor
cell aggregation (96). In another human melanoma mouse model
study, it was found that N-terminal truncated galectin-3 treatment
was effective in reducing tumor growth and metastasis to axillary
lymph node, but not to lung and liver. This truncated galectin-
3 form is thought to act as a dominant-negative inhibitor since
it retains the ability to bind carbohydrates and competes with
endogenous galectin-3 for carbohydrate binding sites. Consider-
ing that this truncated galectin-3 form lacks the ability to dimerize
or oligomerize, galectin-3 would become unable to cross-link its
binding partners on the cell surface and the ECM and to form
lattice structures, thereby modulating tumor cell changes in terms
of adhesion, signaling, motility, and invasion (97).
The prognostic value of galectin-3 expression in cancer patients
is still a subject of discussion (76, 98). Nonetheless, galectin-3 has
emerged as a useful parameter in diagnosis and/or prognosis of
some malignancies (99–101). Extending the knowledge on the
effects of extracellular galectin-3 on several cells that comprise the
tumor microenvironment, as well as, extending the knowledge on
galectin-3 specific functions in the different tumor types, will pro-
vide valuable support for diagnosis, prognosis, and cancer therapy
advances. However, caution should be taken in extrapolating data
from galectin-3 activity in in vitro and in vivo models to the clin-
ical situation. In this regard, it will be pertinent and timely to
further investigate galectin-3 expression in tissue sections of can-
cer patients and relate these findings to clinical history in order to
determine the potential value of galectin-3 detection for routine
histopathological application.
Considering that many of the studies with exogenous addi-
tion of galectin-3, aiming to explore its biological function, were
performed with high concentrations of the protein, doubts could
rise concerning the relevance of extracellular galectin-3 in all
physiological and pathophysiological conditions mentioned here.
However, considering that stromal cells seem to contribute directly
to the pool of extracellular galectin-3, or indirectly through mod-
ulation of galectin-3 expression and/or secretion by tumor cells
(27, 76, 82), it is reasonable to speculate that, in certain circum-
stances, the high concentrations of galectin-3 used in vitro might
be achieved in vivo.
It is also important to mention that most galectin-3 studies
were conducted using bi-dimensional culture models. However,
the emergence of three-dimensional models for cell culturing in
the last two decades allows the consideration of new aspects of
cell behavior in vitro. Three-dimensional culture models allow
cells to mimic their in vivo architecture with a more complex
ECM arrangement, as well as a different distribution pattern of
cell surface molecules (80, 102). Additional studies that take into
account these changes in cell and environment architecture could
be of great potential to reveal other putative binding partners,
contributing to explain known functions or even unveiling new
functions of galectin-3.
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